T. Rowe Price Associates
ACHV icon

T. Rowe Price Associates’s Achieve Life Sciences ACHV Stock Holding History

T. Rowe Price Associates’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$423K Buy
+64,769
New +$309K ﹤0.01% 2692
2025
Q2 		– Sell
-13,474
Closed -$36K – 3059
2025
Q1 		$36K Hold
13,474
– – ﹤0.01% 2962
2024
Q4 		$48K Buy
13,474
+2,389
+22% +$10.8K ﹤0.01% 2948
2024
Q3 		$53K Hold
11,085
– – ﹤0.01% 2919
2024
Q2 		$0 Buy
+11,085
New +$53.4K ﹤0.01% 2922
2017
Q3 		– Sell
-21
Closed -$17K – 2570
2017
Q2 		$17K Hold
21
– – ﹤0.01% 2548
2017
Q1 		$20K Hold
21
– – ﹤0.01% 2562
2016
Q4 		$23K Hold
21
– – ﹤0.01% 2541
2016
Q3 		$23K Hold
21
– – ﹤0.01% 2517
2016
Q2 		$46K Hold
21
– – ﹤0.01% 2481
2016
Q1 		$32K Hold
21
– – ﹤0.01% 2484
2015
Q4 		$56K Hold
21
– – ﹤0.01% 2470
2015
Q3 		$103K Buy
21
+5
+31% +$30.1K ﹤0.01% 2405
2015
Q2 		$84K Buy
16
+1
+7% +$4.96K ﹤0.01% 2475
2015
Q1 		$70K Buy
15
+4
+36% +$19.6K ﹤0.01% 2499
2014
Q4 		$56K Buy
11
+3
+38% +$14.7K ﹤0.01% 2513
2014
Q3 		$47K Hold
8
– – ﹤0.01% 2522
2014
Q2 		$65K Buy
+8
New +$98.3K ﹤0.01% 2497

Other funds holding ACHV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

T. Rowe Price Associates's ACHV Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Achieve Life Sciences (ACHV) in Q2 2026: 64,769 shares worth $423K. The stake represents ﹤0.01% of the portfolio and ranks #2692 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in ACHV as recently as Q1 2025.

T. Rowe Price Associates first reported a position in ACHV in Q2 2014 and has held it in 18 quarters since. 111 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

  • T. Rowe Price Associates held 64,769 shares of Achieve Life Sciences worth $423K as of Q2 2026.
  • Achieve Life Sciences was a new T. Rowe Price Associates position in Q2 2026.
  • Achieve Life Sciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2692 holding.
  • T. Rowe Price Associates first reported a position in Achieve Life Sciences in Q2 2014 and has held it in 18 quarters since.
  • 111 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.